Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-015543

Chief Financial Officer acquired 3,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Goeltz II Robert C. · Chief Financial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2017-04-10 Exercise or conversion : show line 1 in the form +3,000 $4.47 $13,418 12,789 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2017-04-10 Exercise or conversion : show line 2 in the form Stock Option (Right to Buy) −3,000 214,658 D
Loading xslF345X03/doc1.xml…